InterMune Inc. (ITMN) announced after the close Tuesday that Health Canada has approved Esbriet for the treatment of mild to moderate idiopathic pulmonary fibrosis in adult patients. The stock is now up 0.30 on 24K shares.
InterMune traded in a range for the majority of Tuesday's session and closed down by 0.21 at $8.85. The stock closed testing the lower end of a 2 1/2 week range.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org